Robert D. Hardie - Jul 6, 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
10%+ Owner
Signature
/s/ Katherine Denby, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jul 6, 2021
Transactions value $
$12,000,000
Form type
4
Date filed
7/8/2021, 06:14 PM
Previous filing
Jun 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Conversion of derivative security +1.12M 1.12M Jul 6, 2021 See footnote F1, F2
transaction ABOS Common Stock Conversion of derivative security +2.08M +184.59% 3.2M Jul 6, 2021 See footnotes F1, F3
transaction ABOS Common Stock Purchase $12M +750K +23.43% $16.00 3.95M Jul 6, 2021 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Series A-1 Preferred Stock Conversion of derivative security $0 -1.12M -100% $0.00* 0 Jul 6, 2021 Common Stock 1.12M See footnote F1, F2
transaction ABOS Series B Preferred Stock Conversion of derivative security $0 -2.08M -100% $0.00* 0 Jul 6, 2021 Common Stock 2.08M See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Robert D. Hardie is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2 Consists of 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by H7 Holdings LLC, and 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein.
F3 Consists of 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by H7 Holdings LLC, and 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein.
F4 Consists of 375,000 shares of common stock held by H7 Holdings LLC, and 375,000 shares of common stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein.